Related Experiment Video

Updated: Oct 16, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Arteriosclerosis and the promise of GPIIb/IIIa inhibitors in stroke

G Saposnik1, L R Caplan

  • 1Department of Neurology, Ramos Mejia Hospital, Buenos Aires University, Argentina. gsaposnik@yahoo.com

Arquivos De Neuro-Psiquiatria
|April 19, 2000
PubMed

Insights

New antiplatelet drugs targeting glycoprotein (GP) IIb/IIIa receptors show promise in preventing ischemic events. While effective in acute coronary syndromes, their role in stroke prevention requires further investigation due to potential bleeding risks.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Pharmacology

Background:

  • Ischemic mechanisms have been studied for over 150 years, with antiplatelet agents showing benefit in secondary prevention.
  • Aspirin is a common antiplatelet drug, but current regimens offer less than 40% benefit in stroke prevention.
  • Platelet adherence and aggregation are crucial in thrombus formation, mediated by receptors like glycoprotein (GP) IIb/IIIa.

Purpose of the Study:

  • To review clinical trials of new GP IIb/IIIa inhibitors in myocardial ischemia.
  • To consider the potential implications of these agents for cerebrovascular disease prevention.
  • To evaluate the effectiveness and safety of novel antiplatelet strategies.

Main Methods:

  • Review of clinical trials involving GP IIb/IIIa inhibitors.
  • Analysis of data from studies on acute coronary syndromes.
  • Assessment of potential risks and benefits for stroke prevention.

Main Results:

  • GP IIb/IIIa inhibitors have demonstrated effectiveness in acute coronary syndromes.
  • Limited studies exist on their use in cerebrovascular disease.
  • Potential hemorrhagic complications raise concerns for stroke prevention.

Conclusions:

  • New GP IIb/IIIa agents represent a potential advancement in antiplatelet therapy.
  • Further research is needed to establish their efficacy and safety in stroke prevention.
  • Balancing antithrombotic benefits against hemorrhagic risks is critical.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...